CVRx, Inc. - Common Stock (CVRX)
0.6301
-0.0701 (-10.01%)
NASDAQ · Last Trade: Nov 13th, 12:48 AM EST
Detailed Quote
| Previous Close | 0.7002 |
|---|---|
| Open | 0.6984 |
| Bid | 0.6300 |
| Ask | 0.6700 |
| Day's Range | 0.6301 - 0.7011 |
| 52 Week Range | 0.6301 - 10.28 |
| Volume | 591,874 |
| Market Cap | 16.65M |
| PE Ratio (TTM) | -0.3150 |
| EPS (TTM) | -2.0 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 770,558 |
Chart
About CVRx, Inc. - Common Stock (CVRX)
Cvrx Inc. is a medical technology company focused on developing and commercializing innovative solutions for the treatment of cardiovascular diseases. The company specializes in advancing minimally invasive therapies that aim to improve heart function and enhance the quality of life for patients suffering from conditions such as heart failure. By leveraging cutting-edge technology and research, Cvrx Inc. is dedicated to addressing the unmet needs in the cardiovascular space and providing healthcare professionals with effective tools to manage patient care. Through its commitment to innovation, the company strives to make a meaningful impact in the field of cardiology and transform patient outcomes. Read More
News & Press Releases
Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against CVRx, Inc. (“CVRx” or “the Company”) (NASDAQ: CVRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
By Schall, Brown & Schwartz LLP · Via Business Wire · November 12, 2026
A securities fraud class action lawsuit has been filed against CVRx, Inc. ("CVRx" or the "Company") (NASDAQ: CVRX) on behalf of investors who purchased or otherwise acquired the Company's securities between July 25, 2023 and August 6, 2026, inclusive. Glancy Prongay Wolke & Rotter LLP ("Glancy") today announced the filing. The CVRx, Inc. case, Oklahoma Police Pension and Retirement System v. CVRx, Inc. et al., was filed on November 9, 2026 in the U.S. District Court District of Minnesota (Case No. 0:26-cv-04746). CVRx, Inc. investors have until January 8, 2027 to file a lead plaintiff motion.
By Glancy Prongay Wolke & Rotter LLP · Via Business Wire · November 11, 2026
CVRx, Inc. ("CVRx" or the "Company") (NASDAQ: CVRX) is the subject of a securities fraud class action lawsuit filed on behalf of investors who purchased or otherwise acquired the Company's securities from July 25, 2023 through August 6, 2026, inclusive. The Law Offices of Howard G. Smith today reported the lawsuit, Oklahoma Police Pension and Retirement System v. CVRx, Inc. et al., which was filed on November 9, 2026 in the U.S. District Court District of Minnesota (Case No. 0:26-cv-04746). The deadline for CVRx, Inc. investors to file a lead plaintiff motion is January 8, 2027.
By The Law Offices of Howard G. Smith · Via Business Wire · November 11, 2026
NEW YORK, Nov. 10, 2026 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · November 10, 2026
Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of CVRx, Inc. (NASDAQ: CVRX) between July 25, 2023 and August 6, 2026, inclusive (the “Class Period”). CVRx is a commercial-stage medical device company.
By The Rosen Law Firm, P.A. · Via Business Wire · November 10, 2026
A securities class action lawsuit has been filed against CVRx, Inc. ("CVRx" or the "Company") (NASDAQ: CVRX) on behalf of investors who purchased or otherwise acquired CVRx, Inc. securities from July 25, 2023 to August 6, 2026, inclusive. The Law Offices of Frank R. Cruz today reported the case, Oklahoma Police Pension and Retirement System v. CVRx, Inc. et al., filed on November 9, 2026 in the U.S. District Court District of Minnesota (Case No. 0:26-cv-04746). Lead plaintiff motions in the CVRx, Inc. case are due by January 8, 2027.
By Law Offices of Frank R. Cruz · Via Business Wire · November 10, 2026
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired CVRx, Inc. (“CVRx” or the “Company”) (NASDAQ: CVRX) securities between July 25, 2023 and August 6, 2026, inclusive (“the Class Period”). If you suffered a loss on your CVRx investments, you have until January 8, 2027 to request lead plaintiff appointment.
By Kirby McInerney LLP · Via Business Wire · November 10, 2026
Shareholder rights law firm Robbins LLP informs investors that a class action was filed on behalf of all persons who purchased or otherwise acquired CVRx, Inc. (NASDAQ: CVRX) common stock between July 25, 2023 and August 6, 2026, inclusive (the “Class Period”). CVRx is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular disease.
By Robbins LLP · Via Business Wire · November 9, 2026
Top US Stock Gainers and Losers in Today's Sessionchartmill.com
Via Chartmill · November 6, 2026
Top US Stock Gainers and Losers: Nov. 6, 2026 Sessionchartmill.com
Via Chartmill · November 6, 2026
Payer delays and specialist turnover weighed on results and guidance.
Via The Motley Fool · November 6, 2026
Gap Stocks in Today's Sessionchartmill.com
Via Chartmill · November 6, 2026
Top movers analysis one hour before the close of the markets on 2026-09-30: top gainers and losers in today's session.chartmill.com
Via Chartmill · September 30, 2026
Let's take a look at the stocks that are in motion in today's session.chartmill.com
Via Chartmill · September 30, 2026
NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of CVRx, Inc. (“CVRx” or the “Company”) (NASDAQ: CVRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · September 1, 2026
One of J&J's investments stands head-and-shoulders above the rest.
Via The Motley Fool · August 31, 2026
NEW YORK, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of CVRx, Inc. (“CVRx” or the “Company”) (NASDAQ: CVRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · August 25, 2026
These stocks have an unusual volume in today's sessionchartmill.com
Via Chartmill · August 14, 2026
U.S. heart failure revenue surged 21% amid reimbursement gains and sales expansion challenges.
Via The Motley Fool · August 13, 2026
These stocks have an unusual volume in today's sessionchartmill.com
Via Chartmill · August 13, 2026
CVRx (NASDAQ:CVRX) outlined its efforts to expand adoption of its Barostim therapy for heart failure patients, emphasizing sales-force execution, payer coverage progress and a large post-market clinical trial during Canaccord Genuity’s 46th Annual Growth Conference.
President and CEO Kevin Hykes sa
Via MarketBeat · August 13, 2026
The Law Offices of Frank R. Cruz announces an investigation of CVRx, Inc. (“CVRx” or the “Company”) (NASDAQ: CVRX) on behalf of investors concerning the Company’s possible violations of federal securities laws.
By The Law Offices of Frank R. Cruz · Via Business Wire · August 11, 2026
Law Offices of Howard G. Smith announces an investigation on behalf of CVRx, Inc. (“CVRx” or the “Company”) (NASDAQ: CVRX) investors concerning the Company’s possible violations of federal securities laws.
By Law Offices of Howard G. Smith · Via Business Wire · August 11, 2026
Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of CVRx, Inc. (“CVRx” or the “Company”) (NASDAQ: CVRX) investors concerning the Company’s possible violations of the federal securities laws.
By Glancy Prongay Wolke & Rotter LLP · Via Business Wire · August 10, 2026
In today's session, these stocks are experiencing unusual volume.chartmill.com
Via Chartmill · August 10, 2026